Facebook
Twitter
LinkedIn
Forward
This session covers new AASLD guidelines for screening, disease associations, diagnosis, and treatments.CME/CE Expiration Date: 10/27/26
|
Treatment of people with unhealthy weight has typically focused on those with obesity or in those with BMI ≥ 27 with existing comorbidities; however, evidence indicates that the negative effects of
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss.
|
This session will review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
The session will begin by providing a general overview of the prevalence and epidemiology of nonalcoholic fatty liver disease.
|
Obesity is one of the leading causes of the development of type 2 diabetes mellitus.
|
Sarcopenic obesity presents numerous risks to health and quality of life.
|
Review some common definitions of metabolic syndrome and its relationship to the underlying driving force behind its development, insulin resistance.
|
Explore the direct and indirect connections between obesity and heart disease, as well as practical strategies for managing heart disease through obesity treatment.
|